Radiopharm Theranostics Limited American Depositary Shares (RADX NASDAQ) stock market data APIs
$1.002
0.07(7%)
as of November 2, 2026
Try our APIs with
free plan!
Radiopharm Theranostics Limited American Depositary Shares Financial Data Overview
Price chart is built with
Anychart
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. It is also developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; and RAD402, a PSA-mAb prostate cancer therapeutic. The company was incorporated in 2021 and is based in Carlton, Australia.
Prev. Close
1.002
Open
1.0696
High
1.074
Low
0.9992
52 wk Range
0.9-10.63
Market Cap
16 959 K
Shares Outstanding
15 703 K
Revenue
12 865 K
EPS
0
Beta
0.86
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Radiopharm Theranostics Limited American Depositary Shares data using free add-ons & libraries
Get Radiopharm Theranostics Limited American Depositary Shares Fundamental Data
Radiopharm Theranostics Limited American Depositary Shares Fundamental data includes:
- Net Revenue: 12 865 K
- EBITDA: -50 251 072
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Radiopharm Theranostics Limited American Depositary Shares Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-02-26
- EPS/Forecast: 0
Get Radiopharm Theranostics Limited American Depositary Shares End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Radiopharm Theranostics Limited American Depositary Shares News
New
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
GE HealthCare Technologies GEHC recently announced that its MINItrace Magni cyclotron has received CE Mark certification, advancing the company's efforts to expand local production of radioisotopes us...
Radiopharm Theranostics Reports Business Update
Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint Plans to initiate Phase 3 reg...
Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
NEW YORK and SYDNEY, July 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics Limited (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company foc...
Radiopharm Theranostics Reports Positive Trial Updates For RAD101 And RAD204
(RTTNews) - Radiopharm Theranostics Ltd. (RADX), a clinical-stage biopharmaceutical company developing radiopharmaceuticals for oncology, announced two key clinical updates today from its pipeline pro...
Get Radiopharm Theranostics Limited American Depositary Shares fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.